Skip to content
Disclosery

EXANE DERIVATIVES: ACN position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on ACN, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 1,447 ACN shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 1,447 shares
    Change vs previous 13F -767 shares

    0.23% of the 13F portfolio, value $401,717.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 2,214 shares
    Change vs previous 13F +1,206 shares

    0.21% of the 13F portfolio, value $746,632.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 1,008 shares
    Change vs previous 13F +8 shares

    0.1% of the 13F portfolio, value $417,880.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 1,000 shares
    Change vs previous 13F 0 shares

    0.08% of the 13F portfolio, value $319,933.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 1,000 shares
    Change vs previous 13F 0 shares

    0.07% of the 13F portfolio, value $312,637.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 1,000 shares
    Change vs previous 13F not available

    0.08% of the 13F portfolio, value $276,263.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).